{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:32:28Z","timestamp":1792099948127,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03578-w","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T14:39:24Z","timestamp":1734014364000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Long-term adverse event risks of oral JAK inhibitors versus immunomodulators: a literature review"],"prefix":"10.1007","volume":"317","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9206-476X","authenticated-orcid":false,"given":"Olivia","family":"Lamberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Pandher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon P.","family":"Troost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry W.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"issue":"4","key":"3578_CR1","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","volume":"76","author":"W Damsky","year":"2017","unstructured":"Damsky W, King BA (2017) JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol 76(4):736\u2013744. https:\/\/doi.org\/10.1016\/j.jaad.2016.12.005","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"3578_CR2","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1080\/09546634.2018.1546043","volume":"30","author":"P Ciechanowicz","year":"2019","unstructured":"Ciechanowicz P, Rakowska A, Sikora M, Rudnicka L (2019) JAK-inhibitors in dermatology: current evidence and future applications. J Dermatolog Treat 30(7):648\u2013658. https:\/\/doi.org\/10.1080\/09546634.2018.1546043","journal-title":"J Dermatol Treat"},{"issue":"4","key":"3578_CR3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s40257-022-00701-3","volume":"23","author":"SB Elmariah","year":"2022","unstructured":"Elmariah SB, Smith JS, Merola JF (2022) JAK in the [Black] box: a dermatology perspective on systemic JAK inhibitor safety. Am J Clin Dermatol 23(4):427\u2013431. https:\/\/doi.org\/10.1007\/s40257-022-00701-3","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"3578_CR4","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","volume":"82","author":"A Menter","year":"2020","unstructured":"Menter A, Gelfand JM, Connor C et al (2020) Joint\u00a0American academy of dermatology-national psoriasis foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol 82(6):1445\u20131486. https:\/\/doi.org\/10.1016\/j.jaad.2020.02.044","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"3578_CR5","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/jdv.18345","volume":"36","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Kinberger M, Arents B et al (2022) European guideline (EuroGuiDerm) on atopic eczema: part I-systemic therapy. J Eur Acad Dermatol Venereol 36(9):1409\u20131431. https:\/\/doi.org\/10.1111\/jdv.18345","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"3578_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jaad.2017.04.1142","volume":"78","author":"LC Strazzulla","year":"2018","unstructured":"Strazzulla LC, Wang EHC, Avila L et al (2018) Alopecia areata: an appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol 78(1):15\u201324. https:\/\/doi.org\/10.1016\/j.jaad.2017.04.1142","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"3578_CR7","first-page":"566","volume":"19","author":"R Bissonnette","year":"2020","unstructured":"Bissonnette R, Langholff W (2020) Evaluation of risk of major adverse cardiovascular events with biologic therapy in patients with psoriasis (Errata). J Drugs Dermatol 19(6):566\u2013570","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"3578_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","volume":"76","author":"LY Liu","year":"2017","unstructured":"Liu LY, Craiglow BG, Dai F, King BA (2017) Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol 76(1):22\u201328. https:\/\/doi.org\/10.1016\/j.jaad.2016.09.007","journal-title":"J Am Acad Dermatol"},{"issue":"16","key":"3578_CR9","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O et al (2017) Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med 377(16):1537\u20131550. https:\/\/doi.org\/10.1056\/NEJMoa1615975","journal-title":"N Engl J Med"},{"issue":"1","key":"3578_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","volume":"21","author":"J Wollenhaupt","year":"2019","unstructured":"Wollenhaupt J, Lee EB, Curtis JR et al (2019) Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther 21(1):89. https:\/\/doi.org\/10.1186\/s13075-019-1866-2","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"3578_CR11","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/apt.16712","volume":"55","author":"WJ Sandborn","year":"2022","unstructured":"Sandborn WJ, Lawendy N, Danese S et al (2022) Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE open, an open-label, long-term extension study with up to 7.0 years of treatment. Aliment Pharmacol Ther 55(4):464\u2013478. https:\/\/doi.org\/10.1111\/apt.16712","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"3578_CR12","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","volume":"76","author":"SB Cohen","year":"2017","unstructured":"Cohen SB, Tanaka Y, Mariette X et al (2017) Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5\u2005years: integrated analysis of data from the global clinical trials. Ann Rheum Dis 76(7):1253\u20131262. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210457","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3578_CR13","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jaad.2016.01.013","volume":"74","author":"KA Papp","year":"2016","unstructured":"Papp KA, Krueger JG, Feldman SR et al (2016) Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol 74(5):841\u2013850. https:\/\/doi.org\/10.1016\/j.jaad.2016.01.013","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"3578_CR14","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/ecco-jcc\/jjac141","volume":"17","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn WJ, D\u2019Haens GR, Sands BE et al (2023) Tofacitinib for the treatment of ulcerative colitis: an integrated summary of up to 7.8 Years of safety data from the global clinical programme. J Crohns Colitis 17(3):338\u2013351. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac141. (published correction appears in J Crohns Colitis. 2022 Dec 29;:)","journal-title":"J Crohns Colitis"},{"issue":"2","key":"3578_CR15","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/jdv.16948","volume":"35","author":"T Bieber","year":"2021","unstructured":"Bieber T, Thyssen JP, Reich K et al (2021) Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol 35(2):476\u2013485. https:\/\/doi.org\/10.1111\/jdv.16948","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"3578_CR16","doi-asserted-by":"publisher","first-page":"2161812","DOI":"10.1080\/09546634.2022.2161812","volume":"34","author":"T Bieber","year":"2023","unstructured":"Bieber T, Katoh N, Simpson EL et al (2023) Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials. J Dermatolog Treat 34(1):2161812. https:\/\/doi.org\/10.1080\/09546634.2022.2161812","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"3578_CR17","doi-asserted-by":"publisher","first-page":"e002012","DOI":"10.1136\/rmdopen-2021-002012","volume":"8","author":"R Fleischmann","year":"2022","unstructured":"Fleischmann R, Mysler E, Bessette L et al (2022) Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study [published correction appears in RMD Open. 2023;9(2)]. RMD Open 8(1):e002012. https:\/\/doi.org\/10.1136\/rmdopen-2021-002012","journal-title":"RMD Open"},{"issue":"3","key":"3578_CR18","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.jaci.2021.07.036","volume":"149","author":"JI Silverberg","year":"2022","unstructured":"Silverberg JI, de Bruin-Weller M, Bieber T et al (2022) Upadacitinib plus topical corticosteroids in atopic dermatitis: week 52 AD up study results. J Allergy Clin Immunol 149(3):977-987e14. https:\/\/doi.org\/10.1016\/j.jaci.2021.07.036","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"3578_CR19","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.cgh.2021.12.030","volume":"20","author":"G D\u2019Haens","year":"2022","unstructured":"D\u2019Haens G, Pan\u00e9s J, Louis E et al (2022) Upadacitinib was efficacious and well-tolerated over 30 months in patients with crohn\u2019s disease in the CELEST extension study. Clin Gastroenterol Hepatol 20(10):2337-2346e3. https:\/\/doi.org\/10.1016\/j.cgh.2021.12.030","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"3578_CR20","doi-asserted-by":"publisher","first-page":"e002280","DOI":"10.1136\/rmdopen-2022-002280","volume":"8","author":"D Van der Heijde","year":"2022","unstructured":"Van der Heijde D, Deodhar A, Maksymowych WP et al (2022) Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension. RMD Open 8(2):e002280. https:\/\/doi.org\/10.1136\/rmdopen-2022-002280","journal-title":"RMD Open"},{"issue":"1","key":"3578_CR21","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s13555-022-00842-7","volume":"13","author":"N Katoh","year":"2023","unstructured":"Katoh N, Ohya Y, Murota H et al (2023) Safety and efficacy of upadacitinib for atopic dermatitis in Japan: 2-Year interim results from the phase 3 rising up study. Dermatol Ther (Heidelb) 13(1):221\u2013234. https:\/\/doi.org\/10.1007\/s13555-022-00842-7","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"3578_CR22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1136\/annrheumdis-2021-221051","volume":"81","author":"KL Winthrop","year":"2022","unstructured":"Winthrop KL, Tanaka Y, Takeuchi T et al (2022) Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. Ann Rheum Dis 81(2):184\u2013192. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221051","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3578_CR23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1046\/j.1523-1747.2003.12040.x","volume":"120","author":"CF Paul","year":"2003","unstructured":"Paul CF, Ho VC, McGeown C et al (2003) Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 120(2):211\u2013216. https:\/\/doi.org\/10.1046\/j.1523-1747.2003.12040.x","journal-title":"J Invest Dermatol"},{"issue":"5","key":"3578_CR24","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1007\/s12325-021-01713-x","volume":"38","author":"N Khan","year":"2021","unstructured":"Khan N, Pernes T, Weiss A et al (2021) Incidence of infections and malignancy among elderly male patients with IBD exposed to vedolizumab, prednisone, and 5-ASA medications: a nationwide retrospective cohort study. Adv Ther 38(5):2586\u20132598. https:\/\/doi.org\/10.1007\/s12325-021-01713-x","journal-title":"Adv Ther"},{"issue":"3","key":"3578_CR25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1177\/1203475418755998","volume":"22","author":"KA Papp","year":"2018","unstructured":"Papp KA, Bourcier M, Poulin Y et al (2018) OBSERVE-5: comparison of Etanercept-treated psoriasis patients from Canada and the United States. J Cutan Med Surg 22(3):297\u2013303. https:\/\/doi.org\/10.1177\/1203475418755998","journal-title":"J Cutan Med Surg"},{"issue":"6","key":"3578_CR26","doi-asserted-by":"publisher","first-page":"369","DOI":"10.7326\/M19-3369","volume":"172","author":"DH Solomon","year":"2020","unstructured":"Solomon DH, Glynn RJ, Karlson EW et al (2020) Adverse effects of low-dose methotrexate: a randomized trial. Ann Intern Med 172(6):369\u2013380. https:\/\/doi.org\/10.7326\/M19-3369","journal-title":"Ann Intern Med"},{"issue":"3","key":"3578_CR27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CE et al (2017) Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 76(3):405\u2013417. https:\/\/doi.org\/10.1016\/j.jaad.2016.11.041","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"3578_CR28","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/art.40841","volume":"71","author":"PC Taylor","year":"2019","unstructured":"Taylor PC, Weinblatt ME, Burmester GR et al (2019) Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. Arthritis Rheumatol 71(7):1042\u20131055. https:\/\/doi.org\/10.1002\/art.40841","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"3578_CR29","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","volume":"81","author":"PC Taylor","year":"2022","unstructured":"Taylor PC, Takeuchi T, Burmester GR et al (2022) Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis 81(3):335\u2013343. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221276","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"3578_CR30","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1016\/S2352-3026(19)30207-8","volume":"7","author":"JJ Kiladjian","year":"2020","unstructured":"Kiladjian JJ, Zachee P, Hino M et al (2020) Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol 7(3):e226\u2013e237. https:\/\/doi.org\/10.1016\/S2352-3026(19)30207-8","journal-title":"Lancet Haematol"},{"issue":"1","key":"3578_CR31","doi-asserted-by":"publisher","first-page":"8588","DOI":"10.1038\/s41598-021-87766-y","volume":"11","author":"JR Hong","year":"2021","unstructured":"Hong JR, Jeong H, Kim H et al (2021) The potential impact of systemic anti-inflammatory therapies in psoriasis on major adverse cardiovascular events: a Korean nationwide cohort study. Sci Rep 11(1):8588. https:\/\/doi.org\/10.1038\/s41598-021-87766-y","journal-title":"Sci Rep"},{"issue":"4","key":"3578_CR32","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1093\/mr\/roab076","volume":"32","author":"T Takeuchi","year":"2022","unstructured":"Takeuchi T, Hashimoto H, Matsumoto M (2022) Long-term safety and effectiveness of mycophenolate mofetil in adults with lupus nephritis: a real-world study in Japan. Mod Rheumatol 32(4):746\u2013754. https:\/\/doi.org\/10.1093\/mr\/roab076","journal-title":"Mod Rheumatol"},{"issue":"3","key":"3578_CR33","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/ajhp\/54.3.285","volume":"54","author":"KA Hood","year":"1997","unstructured":"Hood KA, Zarembski DG (1997) Mycophenolate mofetil: a unique immunosuppressive agent. Am J Health Syst Pharm 54(3):285\u2013294. https:\/\/doi.org\/10.1093\/ajhp\/54.3.285","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"3578_CR34","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/annrheumdis-2020-218510","volume":"80","author":"SB Cohen","year":"2021","unstructured":"Cohen SB, van Vollenhoven RF, Winthrop KL et al (2021) Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 80(3):304\u2013311. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218510. (published correction appears in Ann Rheum Dis. 2021 May;80(5):e83)","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"3578_CR35","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/art.41580","volume":"73","author":"M Yates","year":"2021","unstructured":"Yates M, Mootoo A, Adas M et al (2021) Venous thromboembolism risk with JAK inhibitors: a Meta-analysis. Arthritis Rheumatol 73(5):779\u2013788. https:\/\/doi.org\/10.1002\/art.41580","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"3578_CR36","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamadermatol.2023.4090","volume":"160","author":"JP Ingrassia","year":"2024","unstructured":"Ingrassia JP, Maqsood MH, Gelfand JM et al (2024) Cardiovascular and venous thromboembolic risk with JAK inhibitors in Immune-mediated inflammatory skin diseases: a systematic review and Meta-analysis. JAMA Dermatol 160(1):28\u201336. https:\/\/doi.org\/10.1001\/jamadermatol.2023.4090","journal-title":"JAMA Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03578-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03578-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03578-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T15:03:55Z","timestamp":1734015835000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03578-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3578"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03578-w","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,12]]},"assertion":[{"value":"24 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"OL, KP, and JT have no conflicts of interest to disclose. HWL has\u00a0served as a Speaker for Pfizer. The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"109"}}